Updated on 10 August 2012
Delays in approvals affected a drop in the growth rate over previous year
The bioservices sector witnessed a growth of 15.5 percent in 2011-12 in spite of facing many issues from the regulatory agencies. The sector touched a revenue of $765 million as against last year's revenue of $520 million. The drop in the growth rate over previous year's growth rate was attributed to the delays in getting approvals from the Drug Controller General of India (DCGI) by the clinical research organizations (CROs). There were fewer projects that came to India as compared to previous years.
The clinical research and trials sector witnessed a drop in revenue from exports by about six percent over previous year as most of the sponsors took a wait and watch approach because of prevailing regulatory concerns in the country. This drop has affected the local small and medium CROs. The leading multinational CROs in India such as Quintiles, on the contrary maintained steady growth because of its full service offerings to the local as well as global customers. In all, about 86 percent of the revenue comes from exports, while the rest is from the domestic market. The domestic business has been on the rise as India's leading pharmaceutical and biotechnology companies now have reached a stage where they are looking at conducting trials for their range of pipeline products in different therapeutic areas.
The contract research business, however, has continued to do well as the leading CROs continued to get business from the existing customers. India's leading players in contract research area maintained a good customer base, that helped them to maintain a decent growth during last year.
There are over 115 clinical trial and contract research companies operating in India mainly based out of Bangalore, Mumbai, Hyderabad, and Ahmedabad. These companies have been offering all kinds of services to sponsors. About 10 percent of the companies have revenues of over $36.1 million (Rs 200 crore). Over 60 percent of the companies are doing businesses in the range between $9 million-18 million (Rs 50crore - Rs 100 crore) and about 20 percent of the companies are operating with a revenue of less than $ 9 million.
Indian CROs such as Synchron, Siro Clinpharm, Veeda Clinical Research, Ecron Acunova have already expanded their operations outside India mainly European region and South East Asian region and are continuously scouting for such opportunities. At the same time, all the Top 10 global CROs have established their base in India.